Prostatic Neoplasms, Castration-Resistant

Oncology
5
Pipeline Programs
7
Companies
5
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 6 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
1 program
1
TasquinimodPhase 31 trial
Active Trials
NCT02057666Terminated146Est. May 2015
Arcus Biosciences
1 program
1
EtrumadenantPhase 1/2
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 836845Phase 11 trial
Active Trials
NCT02204072Completed120Est. Jun 2023
Poseida Therapeutics
Poseida TherapeuticsCA - San Diego
1 program
1
P-PSMA-101 CAR-T cellsPhase 1Cell Therapy1 trial
Active Trials
NCT04249947TerminatedEst. Sep 2024
Sagimet Biosciences
Sagimet BiosciencesCA - San Mateo
1 program
1
TVB-2640Phase 11 trial
Active Trials
NCT05743621RecruitingEst. Jan 2029
Astellas
AstellasChina - Shenyang
1 program
EnzalutamideN/A
Bayer
BayerLEVERKUSEN, Germany
1 program
Radium-223N/A1 trial
Active Trials
NCT03563014Completed164Est. Jan 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
IpsenTasquinimod
Sagimet BiosciencesTVB-2640
Poseida TherapeuticsP-PSMA-101 CAR-T cells
Boehringer IngelheimBI 836845
BayerRadium-223

Clinical Trials (5)

Total enrollment: 430 patients across 5 trials

NCT02057666IpsenTasquinimod

Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer

Start: Jan 2014Est. completion: May 2015146 patients
Phase 3Terminated
NCT05743621Sagimet BiosciencesTVB-2640

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

Start: Nov 2023Est. completion: Jan 2029
Phase 1Recruiting
NCT04249947Poseida TherapeuticsP-PSMA-101 CAR-T cells

P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)

Start: Feb 2020Est. completion: Sep 2024
Phase 1Terminated
NCT02204072Boehringer IngelheimBI 836845

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

Start: Nov 2014Est. completion: Jun 2023120 patients
Phase 1Completed
NCT03563014BayerRadium-223

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Start: Jul 2018Est. completion: Jan 2019164 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 430 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)